YTHDF1 and nasopharyngeal carcinoma: Thus, larger, multi-center studies with well-stratified clinical subgroups (e.g., stratified by metastasis status or clinical stage) are needed to further clarify and confirm the clinical utility of YTHDF1 as a prognostic biomarker in NPC.